In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Replimune Group Inc (NASDAQ: REPL) closed the day trading at $10.69 down -3.26% from the previous closing price of $11.05. In other words, the price has decreased by -$3.26 from its previous closing price. On the day, 0.56 million shares were traded. REPL stock price reached its highest trading level at $11.225 during the session, while it also had its lowest trading level at $10.42.
Ratios:
For a better understanding of REPL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.43 and its Current Ratio is at 11.43. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On November 19, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $52.Piper Sandler initiated its Overweight rating on November 19, 2021, with a $52 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’24 when Patel Sushil sold 10,000 shares for $12.42 per share. The transaction valued at 124,200 led to the insider holds 202,014 shares of the business.
Sushil Patel bought 15,000 shares of REPL for $188,550 on Dec 16 ’24. On Nov 18 ’24, another insider, Xynos Konstantinos, who serves as the Chief Medical Officer of the company, sold 7,246 shares for $10.78 each. As a result, the insider received 78,112 and left with 109,885 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REPL now has a Market Capitalization of 851013760 and an Enterprise Value of 362790016.
Stock Price History:
The Beta on a monthly basis for REPL is 1.21, which has changed by 0.29575753 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, REPL has reached a high of $17.00, while it has fallen to a 52-week low of $4.92. The 50-Day Moving Average of the stock is -15.23%, while the 200-Day Moving Average is calculated to be -5.59%.
Shares Statistics:
Over the past 3-months, REPL traded about 724.70K shares per day on average, while over the past 10 days, REPL traded about 814170 shares per day. A total of 77.01M shares are outstanding, with a floating share count of 61.87M. Insiders hold about 19.67% of the company’s shares, while institutions hold 88.63% stake in the company. Shares short for REPL as of 1740700800 were 9141818 with a Short Ratio of 12.61, compared to 1738281600 on 8468312. Therefore, it implies a Short% of Shares Outstanding of 9141818 and a Short% of Float of 16.370001000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Replimune Group Inc (REPL) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.63 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2.65 and -$2.99 for the fiscal current year, implying an average EPS of -$2.81. EPS for the following year is -$2.39, with 3.0 analysts recommending between -$2.22 and -$2.48.
Revenue Estimates
Based on 4 analysts’ estimates, the company’s revenue will be $46.33M in the next fiscal year. The high estimate is $100.33M and the low estimate is $2.4M.
